Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. (Q54466841)

30 May 2018

title

Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. (English)

1 reference

30 May 2018

author name string

Y Fan

1

1 reference

30 May 2018

B H Xu

2

1 reference

30 May 2018

P Yuan

3

1 reference

30 May 2018

F Ma

4

1 reference

30 May 2018

J Y Wang

5

1 reference

30 May 2018

X Y Ding

6

1 reference

30 May 2018

P Zhang

7

1 reference

30 May 2018

Q Li

8

1 reference

30 May 2018

R G Cai

9

1 reference

30 May 2018

publication date

5 December 2012

1 reference

30 May 2018

published in

Annals of Oncology

1 reference

30 May 2018

volume

24

1 reference

30 May 2018

issue

5

1 reference

30 May 2018

page(s)

1219-1225

1 reference

30 May 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Triple negative tumours: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Pattern of metastatic spread in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Is capecitabine efficacious in triple negative metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS603

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS603

1 reference

30 May 2018

PubMed ID

23223332

1 reference

30 May 2018